Chronic Lung Disease in Medical Literature for More Than 200 Years Finally Has Its First Drug

Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses. The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally…

Read More

So What’s the Deal with ICHRA?

The number of US employees offered ICHRAs continues to grow. Yet, headwinds – including competition, individual coverage market uncertainty, and complexity – may hamper the ICHRA opportunity.  The post So What’s the Deal with ICHRA? appeared first on MedCity News.

Read More

The Crawfish Chronicles: An NIH Fixed Cost Cap Parable

By GREGROY HOPSON T-Maître Pierre’s Family Restaurant was a Louisiana institution. The kind of place where generations gathered over steaming mountains of boiled crawfish, spicy corn, and seasoned potatoes. A place where Clifton Chenier’s Louisiana Blues & Zydeco played in the background and the waitstaff wore starched white shirts with bright-colored bow ties. The walls…

Read More

Payers Are Putting Profit Over Patients with Denials and Prior Auth Policies, Hospitals Say

Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. Hospital executives think federal regulators need to enact stricter policies that require payers to operate on faster timelines, as well as provide more transparency into their reasons for denying claims. The post Payers Are Putting Profit Over…

Read More